Infanrix And Infanrix-hexa Market Report 2026

Infanrix And Infanrix-hexa Market Overview

• The Infanrix And Infanrix-hexa market growth in the historic period has been driven by expansion of routine immunization programs, rising awareness of pediatric infectious disease prevention • Market expansion is supported by increasing birth rates in emerging economies, expansion of universal immunization coverage • Growth Driver: Impact Of Rising Pertussis Cases On The Growth Of The Infanrix And Infanrix-Hexa Market • North America was the largest region in 2025.

What Is Covered Under Infanrix And Infanrix-hexa Market?

Infanrix and Infanrix-hexa are vaccines that protect infants and young children from several serious infectious diseases. Infanrix is a vaccine designed to protect infants and young children from serious illnesses such as diphtheria, tetanus, and whooping cough (pertussis). It is administered in several doses beginning at 2 months of age, helping to prevent these infections. In contrast, Infanrix-hexa is a combination vaccine that safeguards against six diseases such as diphtheria, tetanus, whooping cough, polio, hepatitis B, and Haemophilus influenza type b (Hib). The main patient demographics of infanrix and infanrix-hexa are infants, children, and adolescents and adults. Infants refer to children under 1 year of age and infanrix and infanrix-hexa are vaccines used to protect infants against multiple infectious diseases. For clinical indications such as diphtheria, tetanus, pertussis (whooping cough), hepatitis b, poliomyelitis, and haemophilus influenzae type b (Hib) It is distributed through various channels such as hospitals, clinics, public health programs, and pharmacies. It has applications in primary vaccination, booster doses, and combination with other vaccines.

What Is The Infanrix And Infanrix-hexa Market Growth Forecast?

The growth in the forecast period can be attributed to increasing birth rates in emerging economies, expansion of universal immunization coverage, rising investments in vaccine manufacturing capacity, growing focus on combination vaccines to reduce dosage burden, increasing participation of global health organizations. Major trends in the forecast period include increasing adoption of combination pediatric vaccines, rising demand for hexavalent immunization programs, growing focus on cold chain optimization, expansion of national childhood vaccination schedules, enhanced emphasis on vaccine safety and compliance.

Global Infanrix And Infanrix-hexa Market Segmentation

1) By Patient Demographics: Infants, Children, Adolescents And Adults 2) By Clinical Indication: Diphtheria, Tetanus, Pertussis (Whooping Cough), Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type B (Hib) 3) By Distribution Channel: Hospitals, Clinics, Public Health Programs, Pharmacies 4) By Application: Primary Vaccination, Booster Doses, Combination With Other Vaccines

What Are The Drivers Of The Infanrix And Infanrix-hexa Market?

The rise in the prevalence of pertussis cases is expected to drive the growth of the Infanrix and Infanrix-hexa market. Pertussis cases refer to the number of reported instances of whooping cough, a highly contagious respiratory disease, during a specific period. The number of pertussis cases has been increasing due to lower vaccination rates, changes in immunity, and the rise in undiagnosed or misdiagnosed cases. The increase in pertussis cases is driving the demand for Infanrix and Infanrix-hexa vaccines as they effectively prevent this highly contagious disease, leading to increased adoption and market growth. For instance, in October 2024, according to the Health Protection Surveillance Centre, an Ireland-based specialist agency for the surveillance of communicable diseases, in 2024, around 514 pertussis cases were recorded in Ireland, marking a significant increase from the previous 18 cases in 2023. Therefore, the rise in the prevalence of pertussis cases will drive the growth of the Infanrix and Infanrix Hexa vaccine market. The rise in healthcare expenditure is expected to propel the growth of the infanrix and infanrix-hexa market going forward. Healthcare expenditure is the total amount spent on healthcare services, including medical treatments, medications, and hospital care, within a specific period. Healthcare expenditure is rising due to an aging population, increasing healthcare needs, advancements in medical technology, and rising prices for services and medications. Rising healthcare spending supports the growth of the Infanrix and Infanrix-hexa market by funding expanded immunization efforts and enhancing vaccine availability. For instance, in May 2024, according to the Organisation for Economic Co-operation and Development, a France-based intergovernmental international organization, reported that in 2024, average health spending in OECD countries was estimated to stand at nearly USD 6 000 per capita (when adjusted for differences in purchasing power). The United States was the highest spender. Therefore, the rise in healthcare expenditure is driving the growth of the infanrix and infanrix-hexa industry. The increase in several child deaths is expected to propel the growth of the infanrix and infanrix-hexa vaccine market going forward. Child death rates refer to the number of children who die under the age of 15 within a specific period. Rising child mortality stems from malnutrition, inadequate healthcare, infectious diseases, poor hygiene, and economic Infanrix and Infanrix-Hexa reduce child mortality by protecting against multiple life-threatening diseases through effective immunization. For instance, in March 2025, according to the United Nations International Children’s Emergency Fund, a US-based United Nations agency, reported that in 2023, 4.8 million children under 5 years of age died. This translates to 13,100 children under the age of 5 dying every day in 2023. Therefore, the increase in several child deaths is going to drive the growth of the infanrix and infanrix-hexa vaccine market.

Key Players In The Global Infanrix And Infanrix-hexa Market

Major companies operating in the infanrix and infanrix-hexa market are GlaxoSmithKline plc

Regional Insights

North America was the largest region in the infanrix and infanrix-hexa market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Infanrix And Infanrix-hexa Market?

The infanrix and infanrix-hexa market consists of sales of Infanrix vaccines for diphtheria, tetanus, and whooping cough, Infanrix-hexa vaccines for diphtheria, tetanus, whooping cough, polio, hepatitis B, and Haemophilus influenzae type b and combination vaccines for infants and young children to protect against multiple infectious diseases. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Infanrix And Infanrix-hexa Market Report 2026?

The infanrix and infanrix-hexa market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the infanrix and infanrix-hexa industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.